新天药业: 第八届董事会第一次独立董事专门会议审核意见

Core Viewpoint - The company is planning to increase its investment in Shanghai Huilun Pharmaceutical Co., Ltd. through a capital increase and share transfer, which is expected to enhance its competitiveness in the small molecule drug sector, particularly in the fields of oncology, cardiovascular, respiratory, and digestive system diseases [1][2]. Summary by Relevant Sections - Investment Details - The company will use its own funds of 40 million yuan for the investment, which includes 20 million yuan for acquiring 2,352,941 shares from Hubei Pinghu Venture Capital Co., Ltd. [1][2]. - Transaction Classification - The capital increase is classified as a related party transaction, while the share acquisition does not directly constitute a related party transaction but is subject to related transaction regulations [2]. - Compliance and Fairness - The agreements for the capital increase and share transfer are in compliance with relevant laws and regulations, ensuring that the pricing is fair and does not harm the interests of the company or its shareholders, particularly minority shareholders [2][3].